Europe Vaccines Market Size, Share, Competitive Landscape and Trend Analysis Report, by Technology Type, by Indication, by End User : Opportunity Analysis and Industry Forecast, 2024-2033

Key Market Dynamics

The Europe vaccines market growth is driven by advancement in vaccine technology, particularly mRNA and vector-based vaccines, which has revolutionized the vaccine development process. These advancements not only enhance vaccine efficacy and safety but also foster public trust in vaccination efforts. In addition, collaborative efforts between European countries and international organizations, such as the World Health Organization (WHO) , have been instrumental in promoting vaccination as a global health priority. Initiatives support vaccine access in low and middle-income countries, positively influencing the Europe market by fostering research and development partnerships and boosting production capacities. 

Furthermore, rise in incidence of vaccine-preventable diseases, alongside the emergence of new pathogens, is also driving the demand for vaccines, compelling governments to prioritize their procurement and distribution which supports the growth during Europe vaccines market forecast period. The European Union's proactive approach to ensuring vaccine accessibility and affordability, along with collaborative efforts between member states, is further propelling the Europe vaccines market share. 

However, resistance to vaccine, fueled by misinformation and concerns about vaccine safety, can significantly impact vaccination rates, as some individuals may refuse or delay immunization may limit the Europe vaccines market share. On the other hand, growing interest in travel and global mobility further necessitates vaccination against various diseases, thereby provides Europe vaccines market opportunity. In addition, rise in public-private partnerships in vaccine research and distribution can catalyze innovation and facilitate faster access to new vaccines, driving the Europe vaccines market growth.

Market Segmentation

The Europe vaccines market size is segmented on the basis of technology type, indication, end user, and country. On the basis of technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. On the basis of indication, the market is classified into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP) , polio, hepatitis, and other indications. On the basis of end user, the market segmented into pediatric, adults, and travelers. Country-wise the Europe vaccines industry is classified into Germany,  France, UK, Italy, Spain, and Rest of Europe.

Industry Trends

• The Pneumococcal Polysaccharide Vaccine (PPV) coverage report for England from April 2022 to March 2023 showed that the estimated coverage among individuals aged 65 years and over was 71.8%, with a slight increase of 1.4% from the previous year. Coverage varied regionally, ranging from 67.2% in London to 73.7% in the Northeast and Yorkshire. Thus, increase in vaccine coverage among individuals indicates growing public awareness and acceptance, which supports market expansion. 

• Starting from September 2023, all secondary school pupils in England (years 7 to 11) were offered a free flu vaccine as a nasal spray through their school vaccination program. This initiative aims to protect children and indirectly safeguard vulnerable populations by reducing flu transmission within communities. 
• The National Influenza Immunisation Programme 2024 to 2025 in Wales aims to enhance flu vaccination uptake among various eligible groups, including children aged two and three, school-aged children, individuals in clinical risk groups, and pregnant women. The program operates within a broader Winter Respiratory Vaccination Programme, integrating flu and COVID-19 vaccinations. 

Competitive Landscape

The key players operating in the Europe vaccines industry include Pfizer, Valneva SE, Viatris Inc., AstraZeneca, Emergex Vaccines, GSK plc., Sanofi, Valneva SE, Bavarian Nordic A/S, Merck & Co., Inc., and Prokarium. These players have adopted various developmental strategies to stay competitive in the market. For instance, in April 2022, Merck announced that the European Commission (EC) approved an expanded indication for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children, and adolescents from 6 weeks to less than 18 years of age.

Key Benefits for Stakeholders

• The report provides a comprehensive analysis of the current market estimations through 2024-2033, which would enable the stakeholders to capitalize on prevailing market opportunities.
• Major countries are mapped according to their revenue contribution to the Europe vaccines market.
• In-depth Europe vaccines market analysis and segmentation assists to determine the prevailing market opportunities.
• Identify key players and their strategic moves in Europe vaccines market.
• Assess and rank the top factors that are expected to affect the growth of Europe vaccines market trends.
• Analyze the market factors in various countries and understand business opportunities.
• Player positioning provides a clear understanding of the present position of key market players.